CymaBay Therapeutics Inc

CymaBay Therapeutics (CBAY) closed at $6.17 on June 12, 1.98% higher than its previous close, 28.01% above its 52-week low of $4.82, and 58.87% below its 52-week high of $15.

On Tuesday, CymaBay Therapeutics (NASDAQ:CBAY) stock rose 127.2% after the company highlighted a positive NASH trial update.

E-commerce represented approximately 1% of total sales in fiscal 2013, 4% in fiscal year 2014, 9% in the first quarter of fiscal 2015, and 9.7% in the second quarter of fiscal 2015.

The company “saw improvement in net sales trends over the course of the quarter as inventory levels recovered and the fall flooring season began.” But the shares are down 49% in the year to date.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company formerly known as Metabolex. It develops therapies to treat metabolic and rare diseases with high unmet need.

Using the company’s partnerships and experience in ophthalmology, it plans to expand into a disease indication with a larger market. The company says it expects to place a new product candidate for this large market opportunity into development some time in 2015.

CymaBay Therapeutics (CBAY) is currently enrolling patients in its Phase 3 registrational trial, ENHANCE, to evaluate the use of its investigational PPARδ (peroxisome proliferator-activated receptor delta) agonist, seladelpar, in PBC (primary biliary cholangitis).

This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.

June 11 turned out to be a terrible day for US biopharmaceutical company CymaBay Therapeutics’ (CBAY) investors.

Yesterday, Achaogen (AKAO) announced that the FDA had approved its antibacterial agent, Zemdri (plazomicin), for adults suffering from complicated urinary tract infections (or cUTI) who don’t have significant treatment options.

Of the 23 analysts covering BioMarin Pharmaceuticals in April 2018, eight analysts gave the stock a “strong buy” rating.

BioMarin Pharmaceuticals’ (BMRN) cash, cash equivalents, and investments increased from $1.3 billion in fiscal 2016 to $1.7 billion in fiscal 2017.

CymaBay Therapeutics’ (CBAY) second product candidate, arhalofenate, is being developed for the treatment of gout.